Hims & Hers Health, Inc. (NYSE:HIMS) Holdings Lifted by Harbour Investments Inc.

Harbour Investments Inc. grew its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 18.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 5,269 shares of the company’s stock after purchasing an additional 833 shares during the period. Harbour Investments Inc.’s holdings in Hims & Hers Health were worth $127,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Crewe Advisors LLC bought a new position in Hims & Hers Health in the 4th quarter worth about $28,000. Raleigh Capital Management Inc. boosted its holdings in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares in the last quarter. Blume Capital Management Inc. boosted its holdings in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after acquiring an additional 1,413 shares in the last quarter. Finally, US Bancorp DE boosted its holdings in shares of Hims & Hers Health by 346.7% in the fourth quarter. US Bancorp DE now owns 1,943 shares of the company’s stock valued at $47,000 after acquiring an additional 1,508 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on HIMS. Leerink Partners increased their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a report on Tuesday, February 25th. Piper Sandler increased their price objective on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, February 25th. Bank of America increased their price objective on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a report on Tuesday, March 18th. Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Finally, Truist Financial raised their target price on shares of Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $37.31.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $34.77 on Friday. The company has a 50 day moving average price of $39.21 and a 200 day moving average price of $28.79. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98. The firm has a market capitalization of $7.72 billion, a price-to-earnings ratio of 79.02 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 4,213 shares of Hims & Hers Health stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $29.98, for a total transaction of $126,305.74. Following the completion of the sale, the chief financial officer now owns 128,365 shares of the company’s stock, valued at $3,848,382.70. This trade represents a 3.18 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Soleil Boughton sold 268,932 shares of Hims & Hers Health stock in a transaction on Monday, January 6th. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the sale, the insider now directly owns 169,803 shares of the company’s stock, valued at $4,712,033.25. This trade represents a 61.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,015,547 shares of company stock valued at $36,146,450 in the last quarter. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.